Biostar Pharmaceuticals Inc (NASDAQ:BSPM) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Shares of Biostar Pharmaceuticals (NASDAQ BSPM) traded down 4.62% on Friday, reaching $1.65. 4,714 shares of the company’s stock were exchanged. The firm’s market cap is $4.39 million. The company has a 50 day moving average price of $1.70 and a 200 day moving average price of $2.47. Biostar Pharmaceuticals has a one year low of $1.57 and a one year high of $7.06.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/06/09/biostar-pharmaceuticals-inc-bspm-lowered-to-sell-at-valuengine.html.

Biostar Pharmaceuticals Company Profile

Biostar Pharmaceuticals, Inc (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co, Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Biostar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostar Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.